Home › Trial NCT01724021
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
- Trial IDNCT01724021
- StatusCompleted
- PhasePhase 3
- Study typeInterventional
- SponsorHoffmann-La Roche
- Enrollment743
- Start date2012-12
- ConditionsDiffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.